Clinical Trials Logo
  1. Home
  2. Age-Related Maculopathy
  3. NCT01577381

Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

Age-Related Maculopathy Clinical Trial

Official title:
A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Rn6g (Pf-04382923) In Subjects With Geographic Atrophy Secondary To Age-related Macular Degeneration

Clinical Trial Summary

The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.

Clinical Trial Description

The trial was terminated early on April 12, 2013 due to an organizational decision, which was not based on safety or efficacy concerns. Subjects who were already enrolled into the study were followed. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01577381
Study type Interventional
Source Pfizer
Contact
Status Terminated
Phase Phase 2
Start date August 2012
Completion date October 2013
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01115387 - GARM II: A Study on the Genetics of Age-related Maculopathy
Completed NCT00775411 - Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD) Phase 2
Completed NCT00511706 - Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD) Phase 2
Terminated NCT00474695 - Study Evaluating Genotypes Using Lucentis N/A
Completed NCT00473642 - Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Phase 4
Completed NCT00759044 - Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function N/A
Completed NCT00056823 - Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD) Phase 1/Phase 2
Recruiting NCT05752045 - OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases N/A
Suspended NCT00460967 - Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis Phase 3
Completed NCT00051129 - Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD) Phase 3
Completed NCT01024998 - Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) Phase 1
Completed NCT01494805 - Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT01003691 - Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy Phase 1
Terminated NCT01122511 - Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration Phase 2
Completed NCT00877032 - Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration Phase 1